866-997-4948(US-Canada Toll Free)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Cancer

No. of Pages : 492 Pages

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H2 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.Bile Duct Cancer (Cholangiocarcinoma).

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Bile Duct Cancer (Cholangiocarcinoma) Overview 7
Therapeutics Development 8
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 10
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 14
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 15
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 18
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 23
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 24
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 87
Drug Profiles 101
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 464
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 467
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 468
Appendix 481

List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016 18
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Comparative Analysis by Late Stage Development, H2 2016 25
Comparative Analysis by Clinical Stage Development, H2 2016 26
Comparative Analysis by Early Stage Development, H2 2016 27
Products under Development by Companies, H2 2016 28
Products under Development by Companies, H2 2016 (Contd..1) 29
Products under Development by Companies, H2 2016 (Contd..2) 30
Products under Development by Companies, H2 2016 (Contd..3) 31
Products under Development by Companies, H2 2016 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2016 33
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2016 34
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 35
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2016 36
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 37
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2016 38
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H2 2016 39
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 40
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 41
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2016 42
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2016 43
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2016 44
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corp, H2 2016 45
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 46
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2016 47
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016 48
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H2 2016 49
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H2 2016 50
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corp, H2 2016 51
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 52
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia International Corp, H2 2016 53
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 54
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 55
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H2 2016 56
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H2 2016 57
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2016 58
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H2 2016 59
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 60
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H2 2016 61
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H2 2016 62
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H2 2016 63
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H2 2016 64
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H2 2016 65
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by INSYS Therapeutics Inc, H2 2016 66
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2016 67
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H2 2016 68
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H2 2016 69
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H2 2016 70
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H2 2016 71
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H2 2016 72
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H2 2016 73
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H2 2016 74
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2016 75
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Ltd, H2 2016 76
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H2 2016 77
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H2 2016 78
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 79
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 80
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H2 2016 81
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H2 2016 82
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H2 2016 83
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2016 84
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H2 2016 85
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H2 2016 86
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2016 87
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H2 2016 88
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 89
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 90
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H2 2016 91
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H2 2016 92
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2016 93
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H2 2016 94
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 95
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H2 2016 96
Assessment by Monotherapy Products, H2 2016 97
Assessment by Combination Products, H2 2016 98
Number of Products by Stage and Target, H2 2016 100
Number of Products by Stage and Mechanism of Action, H2 2016 104
Number of Products by Stage and Route of Administration, H2 2016 108
Number of Products by Stage and Molecule Type, H2 2016 110
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2016 474
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H2 2016 475
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..2), H2 2016 476
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2016 477

List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016 18
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 26
Comparative Analysis by Early Stage Products, H2 2016 27
Assessment by Monotherapy Products, H2 2016 97
Number of Products by Top 10 Targets, H2 2016 99
Number of Products by Stage and Top 10 Targets, H2 2016 99
Number of Products by Top 10 Mechanism of Actions, H2 2016 103
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 103
Number of Products by Routes of Administration, H2 2016 107
Number of Products by Stage and Routes of Administration, H2 2016 107
Number of Products by Molecule Types, H2 2016 109
Number of Products by Stage and Molecule Types, H2 2016 109

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *